Get the Stockscreener App
44.27
2.14%
-0.97
After Hours:
44.27
Mirum Pharmaceuticals Inc stock is traded at $44.27, with a volume of 653.78K.
It is down -2.14% in the last 24 hours and up +6.75% over the past month.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
See More
Previous Close:
$45.24
Open:
$45.27
24h Volume:
653.78K
Relative Volume:
1.32
Market Cap:
$2.16B
Revenue:
$307.03M
Net Income/Loss:
$-99.81M
P/E Ratio:
-21.39
EPS:
-2.0695
Net Cash Flow:
$-27.20M
1W Performance:
+1.33%
1M Performance:
+6.75%
6M Performance:
+5.40%
1Y Performance:
+71.39%
1-Day Range:
$44.20
$46.78
1-Week Range:
$40.00
$47.43
52-Week Range:
$23.83
$54.23
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
Name
Mirum Pharmaceuticals Inc
Sector
Industry
Phone
650-667-4085
Address
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
Compare MIRM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MIRM
Mirum Pharmaceuticals Inc
|
44.27 | 2.16B | 307.03M | -99.81M | -27.20M | -2.0695 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-17-24 | Initiated | Stifel | Buy |
| Dec-18-23 | Reiterated | H.C. Wainwright | Buy |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Nov-13-23 | Initiated | Morgan Stanley | Overweight |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-17-23 | Resumed | Evercore ISI | Outperform |
| Sep-20-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-01-22 | Initiated | Citigroup | Buy |
| Sep-20-21 | Initiated | JP Morgan | Overweight |
| Aug-07-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-03-20 | Initiated | H.C. Wainwright | Buy |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jun-25-20 | Initiated | Robert W. Baird | Outperform |
| Aug-12-19 | Initiated | Citigroup | Buy |
| Aug-12-19 | Initiated | Evercore ISI | Outperform |
| Aug-12-19 | Initiated | Guggenheim | Buy |
| Aug-12-19 | Initiated | ROTH Capital | Buy |
| Aug-12-19 | Initiated | Raymond James | Outperform |
View All
Mirum Pharmaceuticals Inc Stock (MIRM) Latest News
Mirum pharmaceuticals raises 2025 revenue guidance to $435M-$450M driven by robust growth - MSN
Mirum Pharmaceuticals (MIRM) Price Target Raised Following Stron - GuruFocus
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Beyond The Numbers: 4 Analysts Discuss Mirum Pharmaceuticals Stock - Benzinga
Mirum Pharmaceuticals (MIRM) Maintains Market Outperform Rating with Higher Price Target | MIRM Stock News - GuruFocus
Mirum's Q1 Earnings Beat Estimates, 2025 Revenue View Raised - MSN
Volixibat Data from Mirum’s VANTAGE PBC Study Showcased at EASL - Stock Titan
Mirum Pharmaceuticals First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Mirum Pharmaceuticals (MIRM) Price Target Raised Following Strong Revenue Outlook | MIRM Stock News - GuruFocus
Evercore ISI lifts Mirum stock target to $76, maintains outperform By Investing.com - Investing.com Canada
Evercore ISI lifts Mirum stock target to $76, maintains outperform - Investing.com
Mirum Pharmaceuticals Reports Strong Q1 2025 Results - TipRanks
Earnings call transcript: Mirum Pharmaceuticals beats Q1 2025 revenue forecasts - Investing.com
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Mirum Pharmaceuticals beats Q1 estimates, raises 2025 guidance; shares rise - Investing.com Canada
Earnings Flash (MIRM) Mirum Pharmaceuticals Reports Q1 Revenue $111.6M, vs. FactSet Est of $98.4M - marketscreener.com
Earnings Flash (MIRM) Mirum Pharmaceuticals Reports Q1 Loss $0.30 Per Share, vs. FactSet Est of $-0.31 - marketscreener.com
Mirum Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update - Yahoo Finance
Mirum Pharmaceuticals: A Respectable Liver, Rare Disease Franchise With Pipeline Opportunities - Seeking Alpha
Learn to Evaluate (MIRM) using the Charts - news.stocktradersdaily.com
Mirum Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025 - Business Wire
Mirum Pharmaceuticals to Present Data at Upcoming Medical Congresses - DutchNews.nl
Rhythm Pharmaceuticals (RYTM) Moves 5.2% Higher: Will This Strength Last? - Yahoo Finance
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Acquired by Russell Investments Group Ltd. - Defense World
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives $58.20 Consensus Target Price from Analysts - Defense World
Leerink Partnrs Issues Negative Outlook for MIRM Earnings - The AM Reporter
Research Analysts Offer Predictions for MIRM Q1 Earnings - Defense World
Geode Capital Management LLC Grows Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - Defense World
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM): Are Analysts Optimistic? - simplywall.st
FDA Approves Mirum Pharmaceuticals’ Drug For Rare Liver Disease Patients In Tablet Form: Retail Stays Bullish - NewsBreak: Local News & Alerts
Mirum gets FDA nod for tablet version of liver drug, Livmarli - MSN
Mirum stock in focus after FDA nod for Livmarli tablet (MIRM) - Seeking Alpha
Mirum Pharmaceuticals Says FDA Approves Tablet Formulation of Treatment for Cholestatic Pruritus - marketscreener.com
Mirum'S Livmarli Now FDA Approved In Tablet Formulation - marketscreener.com
Mirum’s LIVMARLI Now FDA Approved in Tablet Formulation - Business Wire
FDA Green Lights Game-Changing Tablet Version of Rare Liver Disease Drug LIVMARLI - Stock Titan
Mirum Pharma Expands Team with Major Equity Awards Package for Key New Talent - Stock Titan
Mirum Pharmaceuticals Inc [MIRM] stock was sold by Howe Jolanda at the price of US$0.11 million - knoxdaily.com
KLP Kapitalforvaltning AS Makes New $277,000 Investment in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - Defense World
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Sold by Corebridge Financial Inc. - Defense World
Alagille Syndrome Market Growth to Accelerate in Forecast - openPR.com
(MIRM) Investment Report - news.stocktradersdaily.com
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Purchased by Teacher Retirement System of Texas - Defense World
11 Best Gene Therapy Stocks to Buy According to Analysts - Insider Monkey
Mirum Pharmaceuticals (MIRM) Down 1.9% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
MIRM Stock Sees Decline of Approximately -3.74% in Last Five Days - knoxdaily.com
Mirum Pharmaceuticals Says Livmarli Approved in Japan for Pruritus - MarketScreener
LIVMARLI Now Approved In Japan For ALGS And PFIC - MarketScreener
LIVMARLI Now Approved in Japan for ALGS and PFIC - Business Wire
First-Ever Treatment for ALGS and PFIC Approved in Japan: LIVMARLI Makes History - Stock Titan
Mirum Pharmaceuticals: Set Fair For Share Price MomentumReversing My Sell Call (MIRM) - Seeking Alpha
Mirum Pharmaceuticals Inc Stock (MIRM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.84%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):